EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

mFast‐SeqS ‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer

Khrystany T Isebia iD, Bianca Mostert, Teoman Deger iD, Jaco Kraan, Vanja de Weerd, Esther Oomen-de Hoop, Paul Hamberg, Brigitte C M Haberkorn, Helgi H Helgason, Ronald de Wit, Ron H J Mathijssen, Martijn P Lolkema und 3 weitere

Molecular Oncology · 2023

DOI: 10.1002/1878-0261.13449 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Khrystany T Isebia und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Neoplastic Cells, Circulating, Circulating Tumor DNA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple prognostic biomarkers, including circulating tumour cell (CTC) counts, exist in metastatic castration‐resistant prostate cancer (mCRPC) patients, but none of them have been implemented into daily clinical care. The modified fast aneuploidy screening test‐sequencing system (mFast‐SeqS), which yields a genome‐wide aneuploidy score, is able to reflect the fraction of cell‐free tumour DNA (ctDNA) within cell‐free DNA (cfDNA) and may be a promising biomarker in mCRPC. In this study, we investigated the prognostic value of dichotomized aneuploidy scores (< 5 vs. ≥ 5) as well as CTC counts (< 5 vs. ≥ 5) in 131 mCRPC patients prior to treatment with cabazitaxel. We validated our findings in an independent cohort of 50 similarly treated mCRPC patients. We observed that, similar to the dichotomized CTC count [HR: 2.92; 95% confidence interval (CI);1.84–4.62], dichotomized aneuploidy scores (HR: 3.24; CI: 2.12–4.94) significantly correlated with overall survival in mCRPC patients. We conclude that a dichotomized aneuploidy score from cfDNA is a prognostic marker for survival in mCRPC patients within our discovery cohort and in an independent mCRPC validation cohort. Therefore, this easy and robust minimally‐invasive assay can be readily implemented as a prognostic marker in mCRPC. A dichotomized aneuploidy score might also be used as a stratification factor in clinical studies to account for tumour load.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantNeoplastic Cells, CirculatingCirculating Tumor DNAMaleHumansPrognosisBiomarkers, TumorAneuploidy

Stichwörter der Autor:innen

aneuploidy scoresctDNAmFast-SeqSmetastasisnext generation sequencingprostate cancer

Substanzen

Biomarkers, TumorCirculating Tumor DNA

Autor:innen und Institutionen

  • Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands.
  • Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam/Schiedam, The Netherlands.
  • Department of Medical Oncology, Maasstad Hospital, Rotterdam, The Netherlands.
  • Department of Medical Oncology, Haaglanden Medical Centre, The Hague, The Netherlands.

ORCID-Profile: Khrystany T Isebia, Teoman Deger, John W M Martens

Förderung

  • Sanofi

Zitieren

APA

Isebia, K. T., Mostert, B., Deger, T., Kraan, J., de Weerd, V., Oomen-de Hoop, E., Hamberg, P., Haberkorn, B. C. M., Helgason, H. H., de Wit, R., Mathijssen, R. H. J., Lolkema, M. P., Wilting, S. M., van Riet, J., & Martens, J. W. M. (2023). mFast‐SeqS ‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.13449

Vancouver

Isebia KT, Mostert B, Deger T, Kraan J, de Weerd V, Oomen-de Hoop E, et al. mFast‐SeqS ‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer. Molecular Oncology. 2023. doi:10.1002/1878-0261.13449

BibTeX
@article{Isebia2023,
  author = {Isebia, Khrystany T and Mostert, Bianca and Deger, Teoman and Kraan, Jaco and de Weerd, Vanja and Oomen-de Hoop, Esther and Hamberg, Paul and Haberkorn, Brigitte C M and Helgason, Helgi H and de Wit, Ronald and Mathijssen, Ron H J and Lolkema, Martijn P and Wilting, Saskia M and van Riet, Job and Martens, John W M},
  title = {mFast‐SeqS ‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer},
  journal = {Molecular Oncology},
  year = {2023},
  doi = {10.1002/1878-0261.13449}
}
Kostenlos starten →